Nanjing Medical Focuses On Medical Trust
This article was originally published in PharmAsia News
Nanjing Medical Co. Ltd. (NMC) and Nanjing Medical Group have transferred 66 percent of their combined share in NMC Baixin Pharmacy Co., Ltd. to subsidiary Nanjing Pharmaceutical Co., Ltd. The move seeks to consolidate resources for an integrated procurement and supply chain, enabling Nanjing Medical to maximize its business network and increase sales. NMC is also selling out its 30 percent share in Nanjing MeiRui Pharma Co. Ltd. to the latter's U.S. parent company Cal-Nan Horizon Quest, Inc. Analysts believe the divestment allows NMC to focus on its core business of medical trust. The company aims to increase its trust business from the current 500 million yuan to 1 billion yuan in 2008. (Click here for more - Chinese Language)
You may also be interested in...
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
The UK's Celleron has attracted a "blue chip suite of investors" to an Irish-domiciled spin-off based on the potential of Roche-developed emactuzumab for TGCT, a debilitating orphan disease that causes joint damage and has limited clinical options.
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.